Stories of Success

The PlexPCR® technology from SpeeDx is well-known for infectious disease diagnostics but the same technology has also transformed the field of oncology. Significant improvements in the diagnosis and treatment of cancer have occurred through a licensing partnership with Biocartis.

Biocartis employs PlexPCR® for market-leading multiplex capability in their flagship – Idylla™ platform.

  • Using PlexZyme® and PlexPrime® PCR in the testing cartridge, Idylla™ can detect over 50 gene mutations in a tumour biopsy (FFPE, blood or plasma).
  • PlexPCR® also provides extremely high specificity and sensitivity (Limit of Detection of < 1% and as low as 0.01%), making it ideal for liquid biopsy testing where DNA material is limited.

PlexPCR technology is incorporated into the Idylla cartridge

Currently, PlexZyme® and PlexPrime® technology is used in a range of oncology tests for analysis of biopsies or circulating DNA (ct) with the Idylla™ platform:

  1. Idylla™ KRAS Mutation Test (CE-IVD/TGA), Idylla™ ctKRAS Mutation Test (CE-IVD) and Assay (RUO).
  2. Idylla™ NRAS-BRAF Mutation Test (CE-IVD/TGA), Idylla™ NRAS-BRAF-EGFR Mutation Assay (RUO), Idylla™ ctNRAS-BRAF Mutation Test (CE-IVD) and Assay (RUO).
  3. Idylla™ EGFR Mutation Test (CE-IVD/TGA).

The Idylla™ platform is a fully automated, sample-to-result real-time Polymerase Chain Reaction (PCR) diagnostic system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting.

“The game-changing real-time PCR based technology uses a unique combination of PlexZyme® and PlexPrime®, which allows very high sensitivity and specificity combined with high multiplexing capability” Biocartis*

PlexZyme® and PlexPrime® technology is incorporated into the Idylla platform for fully automated molecular diagnostics

Read more about Biocartis and its products here.

 *Uguen A., Troncone G., “A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day”, J Clin Pathol: first published as 10.1136/jclinpath-2018-205189 on 14 June 2018.